Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertensio...

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Associated Therapies: -

Clinical Trials

NYU Langone Health in the News—Friday, October 11, 2024

NYU Langone Health experts discuss various medical topics, including Kayvon Thibodeaux's wrist surgery, methadone restrictions for opioid addiction, microdiscectomy surgery outcomes, dental residency program expansion, blood pressure measurement accuracy, prescription drug shortages, oral bacteria linked to cancer risk, eyelash serum effects, outdoor walking benefits, IV fluid shortage prevention, vaginal fluid acidity, and postpartum drowsiness.

ema.europa.eu

3 months ago

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19

The Committee for Human Medicinal Products (CHMP) elected Bruno Sepodes as its new chair, effective 21 September. CHMP recommended marketing authorisations for eight new medicines, including Elahere, Hetronifly, Hympavzi, Penbraya, Theralugand, Afqlir, Opuviz, and Pomalidomide Teva. It also recommended extending indications for 12 existing medicines and confirmed the refusal of Syfovre's marketing authorisation. Applications for Durysta, Tecentriq, and Sialanar were withdrawn. CHMP updated Spikevax and Comirnaty vaccines to target new COVID-19 variants.

Bimatoprost

NYU Langone Health in the News—Friday, October 11, 2024

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19

Drug Development Updates